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Abstract
Adenoviral vectors (Ads) have been evaluated in clinical trials for glioma. However, systemic immunity against
the vectors can hamper therapeutic efficacy. We demonstrated that combined immunostimulation and cytotoxic
gene therapy provides long-term survival in preclinical glioma models. Because helper-dependent high-capacity
Ads (HC-Ads) elicit sustained transgene expression, in the presence of antiadenoviral immunity, we engineered
HC-Ads encoding conditional cytotoxic herpes simplex type 1 thymidine kinase and immunostimulatory cy-
tokine Fms-like tyrosine kinase ligand-3 under the control of the TetOn system. Escalating doses of combined
HC-Ads (1 · 108, 1 · 109, and 1 · 1010 viral particles [VP]) were delivered into the rat brain. We assessed neu-
ropathology, biodistribution, transgene expression, systemic toxicity, and behavioral impact at acute and chronic
time points after vector delivery. Histopathological analysis did not reveal any evidence of toxicity or long-term
inflammation at the lower doses tested. Vector genomes were restricted to the injection site. Serum chemistry did
not uncover adverse systemic side effects at any of the doses tested. Taken together, our data indicate that doses
of up to 1 · 109 VP of each HC-Ad can be safely administered into the normal brain. This comprehensive toxicity
and biodistribution study will lay the foundations for implementation of a phase 1 clinical trial for GBM using
HC-Ads.
Introduction
Despite advances in neurosurgical techniques, radio-therapy, and chemotherapy, the prognosis in glioblas-
toma multiforme (GBM) remains poor, with median survival
of 14.6–19.6 months (Stupp et al., 2005; Grossman et al., 2010).
GBM is the most common primary brain tumor in adults, and
its highly infiltrative nature precludes complete surgical re-
section; thus, the tumor almost invariably recurs. Thus, im-
munotherapies are attractive adjuvants for this devastating
disease.
We have developed a combined, conditional cytotoxic/
immune stimulatory gene therapy strategy to treat GBM
(Ali et al., 2005; Candolfi et al., 2009; Curtin et al., 2009; Ghulam
Muhammad et al., 2009). This involves treatment with two
genetically engineered first-generation adenoviral vectors
(Ads) to deliver the conditionally cytotoxic herpes simplex
type 1 (HSV1) thymidine kinase (TK) that kills proliferating
tumor cells in the presence of the prodrug ganciclovir (GCV)
(Dewey et al., 1999) and human soluble Fms-like tyrosine
kinase ligand-3 (Flt3L), which recruits bone marrow-derived
antigen-presenting cells into the brain tumor microenviron-
ment (Ali et al., 2004; Curtin et al., 2006). This strategy has
been shown to be highly effective in several syngeneic
preclinical rodent GBM models, that is, rats bearing intra-
cranial CNS-1, 9L, and F98 tumors (Ali et al., 2005; Ghulam
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Muhammad et al., 2009) and mice bearing intracranial GL26,
GL261, and B16-F10 tumors (Candolfi et al., 2009; Curtin
et al., 2009). In addition, the treatment with Ad-TK plus
Ad-Flt3L induces GBM-specific immunological memory that
is effective in treating intracranial multifocal and peripheral
models of GBM (King et al., 2008a,b; Ghulam Muhammad
et al., 2009). This combined gene therapy strategy received
approval from the U.S. Food and Drug Administration
(FDA) for a phase 1 clinical trial for GBM (BB-IND 14574;
NIH/OBA Protocol # 0907-990; OSU Protocol # 10089).
With the aim to improve the gene delivery platform to
achieve regulatable Flt3L expression and elude antiadeno-
virus immune responses, which could curtail therapeutic
transgene expression, we have developed helper-dependent
high-capacity adenoviral (HC-Ad) vectors expressing HSV1-
TK under the control of a constitutive promoter and human
soluble Flt3L (hsFlt3L) under the control of the tightly reg-
ulatable mCMV-TetOn expression system (Xiong et al., 2006;
Curtin et al., 2008). Using these HC-Ad vectors, we demon-
strated their therapeutic efficacy and high safety profile after
delivery into a large tumor mass in a syngeneic, orthotopic
rat model of GBM (Muhammad et al., 2010; Puntel et al.,
2010b).
In the present study, as a prelude to a novel phase 1
clinical trial for GBM, we conducted a dose-escalation and
biodistribution study of HC-Ad-TetOn-Flt3L plus HC-Ad-
TK when delivered into the naive rat brain to determine the
maximal tolerated dose (MTD) of these vectors. After injec-
tion of 1 · 108, 1 · 109, or 1 · 1010 viral particles (VP) of each
HC-Ad, assessment of brain tissue integrity, immune infil-
trates, vector biodistribution and transgene expression, as
well as putative systemic and neurological toxicity was
conducted on day 5, 1 month, 6 months, or 1 year after vector
delivery. Our data indicate that even at the highest dose
tested, real-time quantitative PCR did not detect evidence of
biodistribution of HC-Ad genomes to peripheral organs, and
behavioral testing did not reveal any vector-mediated ab-
normalities. Peripheral blood cell counts and serum bio-
chemistry were within normal ranges at all time points, at all
doses tested. However, neuropathological assessment re-
vealed evidence of neurotoxicity at the highest dose tested
(1 · 1010 VP of each vector), that is, loss of brain tissue and
high levels of inflammation. We did not detect any evidence
of neurotoxicity or long-term inflammation at either of the
two lower doses tested. HC-Ads are attractive gene delivery
platforms for implementing gene therapy strategies for
neurological disorders, both chronic neurodegenerative dis-
orders and brain cancer. For successful implementation of
these experimental therapies in human patients, it will be
necessary to deliver these vectors into the normal brain pa-
renchyma. The data presented herein constitute the first
comprehensive study of the biodistribution, behavioral im-
pact, and neuropathological implications after delivery of
escalating doses of these vectors into the brain parenchyma,
both at acute and chronic time points after vector delivery.
Such well-controlled, preclinical safety and toxicity studies
are required by the FDA in order to file for a pre-IND/IND
and constitute a major milestone in the path toward im-
plementation of the first phase 1 clinical trial for GBM using
gutless, HC-Ad vectors. These studies would also support




Details of the molecular characterization, rescue, amplifi-
cation, and in vitro characterization of the HC-Ad vectors
were previously published (Candolfi et al., 2006; Xiong et al.,
2006; Muhammad et al., 2010). Briefly, HC-Ad-TK expressed
herpes simplex type 1 thymidine kinase (TK) under the
control of a constitutive murine cytomegalovirus (mCMV)
promoter, and HC-Ad-TetOn-Flt3L expressed human solu-
ble Fms-like tyrosine kinase-3 ligand (Flt3L) under the con-
trol of a tightly regulated mCMV-TetOn inducible expression
system developed by us (Xiong et al., 2006). HC-Ad vectors
used in this study were rescued, amplified, and produced as
described previously (Palmer and Ng, 2011). All experiments
in the present study were performed in accordance with
Good Laboratory Practice (GLP) guidelines. The animal
procedures were carried out in accordance with National
Institutes of Health (NIH, Bethesda, MD) guidelines for the
care and use of laboratory animals and approved by the
Cedars-Sinai Medical Center (Los Angeles, CA) Institutional
Animal Care and Use Committee. The serum hematological
and biochemical analysis was performed at ANTECH
Diagnostics (Irvine, CA), which offers clinical pathology
services in a regulated environment and is fully compliant
with GLP regulations.
Animals
Adult male Lewis rats (220–250 g; Harlan, Indianapolis,
IN) were used. Rats were kept under controlled conditions of
light (12-hr light–dark cycles) and temperature (20–25C)
and fed with standard lab chow and water ad libitum.
Intracranial injections and experiment end points
Starting 2 days before treatment, rats were fed with
doxycycline-mixed chow ad libitum (modified LabDiet labo-
ratory rodent diet 5001 with 2000 ppm doxycycline; PMI
Nutrition International/Purina Mills, Richmond, IN).
Groups of rats were injected unilaterally via the right stria-
tum with any of the three escalating doses of HC-Ad-TK and
HC-Ad-TetON-Flt3L (1 · 108, 1 · 109, or 1 · 1010 VP of each
vector). The vectors were first mixed together and re-
suspended in a final volume of 3 ll of saline. Using a 10-ll
Hamilton syringe fitted with a 26-gauge needle, the vector
mixture was administered at the following stereotactic co-
ordinates: 1 mm anterior and 3.2 mm lateral to the bregma
and the injection volume of 3 ll was delivered in three lo-
cations (1 ll each) at depths of - 5.5, - 5.0, and - 4.5 mm
from the dura. Twenty-four hours after treatment, the rats
received ganciclovir (GCV, 25 mg/kg, intraperitoneal; Roche
Laboratories, Nutley, NJ), twice daily for up to 10 consecu-
tive days. The control group of rats (naive) received 3 ll of
saline at the same stereotactic coordinates as the treatment
groups.
Groups of rats were evaluated 5 days, 1 month, 6 months,
and 1 year after vector delivery to determine biodistribution
of HC-Ad vector genomes, neurotoxicity, peripheral blood
cell counts and serum biochemistry, and circulating levels of
anti-adenovirus neutralizing antibodies and anti-TK anti-
bodies. In addition, the 1-month, 6-month, and 1-year groups
were evaluated for HC-Ad vector-induced behavioral
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deficiencies. All animal procedures were carried out in ac-
cordance with the NIH Guide for the Care and Use of Laboratory
Animals and approved by the Cedars-Sinai Medical Center
Institutional Animal Care and Use Committee.
Serum biochemistry and hematology
Five days, 1 month, 6 months, or 1 year posttreatment,
blood was collected from each animal during euthanasia.
The samples were sent to the laboratory of ANTECH Diag-
nostics (Irvine, CA) for analysis of routine hematological and
biochemical parameters. The median, minimal, and maximal
values for each parameter are shown in the Results section
and supplementary tables (supplementary data are available
online at http://www.liebertpub.com/hgtb).
Circulating neutralizing anti-adenovirus antibodies
The level of adenovirus-specific neutralizing antibodies
was assessed as described previously (Puntel et al., 2010a).
Briefly, serum samples were heat-inactivated at 56C for
30 min and serially diluted 2-fold in minimal essential me-
dium (Invitrogen, Carlsbad, CA) containing 2% fetal bovine
serum (FBS). The range of dilutions was 1:2 to 1:4096. Each
50-ll serum dilution was incubated with 1 · 107 plaque-
forming units (PFU) of first-generation adenoviral vector
expressing b-galactosidase (Ad-b-Gal) (in a 10-ll volume) for
90 min at 37C. The 50 ll of sample containing serum and
virus was then added to the wells of a 96-well plate con-
taining preseeded (1.5 · 104) HEK 293 cells per well and were
incubated at 37C for 1 hr. A further 50 ll of medium con-
taining 10% FBS was added to each well, and the cells were
incubated at 37C for 20 hr before fixing with 4% parafor-
maldehyde in PBS (pH 7.4) and staining with 5-bromo-
4-chloro-indolyl-b-d-galactoside (X-Gal; Sigma-Aldrich,
St. Louis, MO). The neutralizing antibody titer for each
animal is given as the reciprocal of the highest dilution of
serum at which 50% of Ad-b-Gal-mediated transduction was
inhibited.
Anti-TK antibody assay
The titer of anti-TK antibodies in the serum of rats was
assessed as described previously (King et al., 2011). Briefly,
CNS-1 cells were infected with first-generation adenoviral
vector expressing TK (Ad-TK) at a multiplicity of infection of
200 infective units (IU)/cell, or mock infected as a control.
After 72 hr, the cells were harvested and freeze–thawed. Cell
lysates were added to a 96-well plate (cat. no. 442404; Nunc,
Rochester, NY) and incubated overnight at 4C. The serum
samples were then diluted 1:4 and added to wells coated
with cell lysates and incubated for 2 hr at room temperature.
The wells were washed and incubated for 1 hr with rabbit
anti-rat IgG/biotinylated secondary antibody (diluted
1:1000; Dako, Carpinteria, CA); wells containing positive
control rabbit serum were incubated with goat anti-rabbit
IgG/biotinylated secondary antibody (diluted 1:1000; Dako).
Last, the wells were incubated with streptavidin–horseradish
peroxidase (HRP) (R&D Systems, Minneapolis, MN) and
visualized with substrate solution (R&D Systems) at a
wavelength of 500 nm. The percentage change in optical
density was calculated for each sample incubated with TK
cell lysates compared with mock lysates.
Study of vector genome biodistribution
Biodistribution of vector genomes was assessed 5 days,
1 month, 6 months, or 1 year posttreatment. This was
performed as described previously (Muhammad et al., 2010;
Puntel et al., 2010b). Briefly, rats were perfused without any
fixative and 25 mg of tissue sample was harvested from the
following locations: the brain injection site, contralateral
brain hemisphere, cerebellum, brain stem, spleen, liver,
testes, small gut, lung, heart, cervical lymph nodes, kidney,
and lumbar spinal cord. Total DNA was purified and used
for the quantitation of vector genomes by real-time quan-
titative PCR, using a primer and probe specific for the
cosmid sequences contained in the HC-Ad vector backbone
as described previously (Puntel et al., 2006). Vector genome
data are shown as the ratio of vector genomes per 25 mg of
tissue (n = 5 per group). Although the limit of detection for
the qPCR technique is 100 copies (Puntel et al., 2006), for the
qPCR biodistribution studies the limit was determined to be
300 copies. Results from studies in which HC-Ad genome
copies were analyzed in the presence of DNA obtained
from tissues of naive animals showed that the basal level of
detection was affected, and we thus determined the limit of
detection to be 300 copies/25 mg of tissue. We did not
encounter any interference in the detection of vector ge-
nomes by qPCR in brain tissue; we evaluated this in an
experiment in which HC-Ad genomic DNA or pStandard
DNA was spiked into brain tissue genomic DNA. In ad-
dition, with the purpose of analyzing the biodistribution of
Ad vectors as part of an IND application to the FDA, we
spiked DNA extracted from all the 13 rat tissues analyzed,
either with HC-Ad genomic DNA or the control plasmid,
and no interference was detected by qPCR of the specific
target DNA for any of the tissues analyzed (our unpub-
lished data).
Neuropathological analysis
Neuropathological evaluation was performed 5 days, 1
month, 6 months, or 1 year posttreatment. After perfusion
with oxygenated Tyrode’s solution and 4% paraformalde-
hyde (PFA), brains were postfixed in 4% PFA for an addi-
tional 3 days. Sixty-micrometer serial coronal sections were
cut in the immediate vicinity of the injection site, and free-
floating immunocytochemistry was performed as previously
described (Candolfi et al., 2007; King et al., 2008b,c) with
markers for oligodendrocytes and myelin sheath (mouse
monoclonal anti-MBP [myelin basic protein], cat. no.
MAB1580, diluted 1:1000; Chemicon, Temecula, CA), dopa-
minergic nerve terminals (rabbit polyclonal anti-TH [tyrosine
hydroxylase], cat. no. 657012, diluted 1:5000; Calbiochem, La
Jolla, CA), CD8 + T cells (mouse anti-CD8, cat. no. MCA48G,
diluted 1:1000; Serotec, Raleigh, NC), macrophages and mi-
croglia (CD68/ED1, mouse anti-ED1, cat. no. MCA341R,
diluted 1:1000; Serotec), macrophages, microglia, and im-
mune cells (mouse anti-MHC-II, cat. no. MCA46G, diluted
1:1000; Serotec), or transgene expression, that is, TK (rabbit
anti-TK, custom made, diluted 1:10,000) or Flt3L (rabbit anti-
Flt3L, custom made, diluted 1:500). Nissl staining was per-
formed to assess gross histopathological features of the
brains. The stained sections were photographed with a Carl
Zeiss optical Axioplan microscope using Axiovision release
4.6 and Mosaix software (Carl Zeiss, Chester, VA).
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Behavioral analysis
The neurobehavioral impact as a consequence of treatment
using escalating doses of HC-Ad was assessed 1 month, 6
months, and 1 year posttreatment. Testing of amphetamine-
induced rotational behavior, abnormalities in limb use
asymmetry, and spontaneous motor and rearing behavior
was done as described previously in detail (King et al.,
2008b). Briefly, amphetamine-induced rotational behavior
was measured with a RotoMax apparatus and software
(AccuScan Instruments, Columbus, OH) for 90 min after
subcutaneous injection of d-amphetamine sulfate (1.5 mg/
kg; Sigma-Aldrich). To measure forelimb use asym-
metry, contacts made by each forepaw with the wall of a
20.3-cm-wide clear cylinder were scored from videotape over
a 10-min period in slow motion by two independent, ex-
perimentally blinded observers. Forelimb contact with the
walls of the cylinder was scored by measuring only initial
contact with the cylinder walls. Baseline spontaneous loco-
motor and rearing activity was recorded for 30 min in a
40.6 · 40.6 · 38.1 cm closed box, using photobeam breaks and
optical sensors. Spontaneous locomotor and rearing activity
was then monitored for 120 min after subcutaneous injection
of d-amphetamine sulfate (1.5 mg/kg; Sigma-Aldrich). Data
were scored as the total number of beam breaks summed
over the observation period.
Statistical analysis
Statistical analyses were performed with GraphPad Prism
5 (GraphPad Software, San Diego, CA). Data were compared
by one-way analysis of variance (ANOVA) followed by
Tukey’s multiple comparison test. p values less than 0.05
were considered as significant.
Results
Dose escalation of HC-Ad-TetOn-Flt3L plus HC-Ad-TK
delivered into naive rat brain followed
by neuropathological analysis
To examine the effects of HC-Ad-TetOn-Flt3L and HC-Ad-
TK on normal brain architecture and inflammation, we per-
formed a comprehensive neuropathological analysis 5 days,
1 month, 6 months, and 1 year after intrastriatal delivery of
HC-Ads. Naive adult Lewis rats received a combination of
either 1 · 108, 1 · 109, or 1 · 1010 VP of each HC-Ad vector or
saline (Fig. 1a). GCV was administered twice daily for up to
10 days. The rats were fed doxycycline-containing chow for
up to 4 weeks because this schedule was found to be optimal
for therapeutic efficacy (Muhammad et al., 2010). Neuro-
pathological assessment revealed evidence of neurotoxicity
at the highest dose tested (1 · 1010 VP of each HC-Ad; total
dose, 2 · 1010 VP), that is, loss of brain tissue and high levels
of inflammation. We did not encounter any evidence of brain
tissue damage at either of the lower doses tested. Nissl
staining was more prominent 5 days after delivery of the
highest dose of HC-Ad when compared with saline-treated
controls and rats receiving either of the lower vector doses
(1 · 108 and 1 · 109 VP of each vector) (Fig. 1b). Myelin basic
protein and tyrosine hydroxylase immunoreactivity also in-
dicated the presence of tissue damage with the high total
dose of 2 · 1010 VP. There was profuse infiltration of CD8 +
T cells, macrophages, and MHC-II + cells in the injected brain
hemisphere in all groups, including saline-treated controls, at
the acute 5-day time point. However, the observed immune
cell infiltration was much more pronounced with the highest
dose (1 · 1010 VP of each HC-Ad) (Fig. 1b). In addition, there
was mild CD68/ED1 and MHC-II immunoreactivity seen in
the contralateral brain hemisphere of saline-treated and all
vector-treated groups at the early time point, that is, 5 days.
The immune cell infiltration seen in all groups declined
gradually over time, that is, at 1 month, 6 months, and 1 year
after treatment (Fig. 1c; and see Supplementary Fig. S1); no
CD8 + T cells were observed 1 year after treatment with ei-
ther of the lower doses (1 · 108 and 1 · 109 VP of each vector)
or saline (Fig. 1c). Regarding expression of the transgene
proteins in the brain, immunocytochemical analysis revealed
an abundance of cells expressing TK and Flt3L on day 5 after
treatment (Fig. 1b); the presence of transgene-expressing cells
was also evident at 1 and 6 months (Supplementary Fig. S1)
and even at 1 year (Fig. 1c) after HC-Ad delivery. High-
power images are provided for Nissl staining at all doses and
time points tested (Fig. 2). These neuropathological data in-
dicate that 1 · 109 VP of each HC-Ad is the maximal tolerated
dose (MTD) that can be safely administered into the brain of
naive rats.
HC-Ad-TetOn-Flt3L and HC-Ad-TK (plus GCV)-treated
animals do not exhibit neurobehavioral deficits
Because the gene therapy vectors will be delivered into the
surrounding brain parenchyma after tumor resection in pa-
tients with GBM, it is important to assess the occurrence of
any acute and/or chronic neurological deficits elicited by
HC-Ads. To this end, adult naive Lewis rats treated with
escalating doses of HC-Ad-TetOn-Flt3L and HC-Ad-TK were
subjected to a panel of neurobehavioral tests 1 month, 6
months, and 1 year after treatment. Analysis of amphet-
amine-induced total locomotor activity (Fig. 3a; and see
Supplementary Figs. S2a and S3a), total rearing activity (Fig.
3b; and see Supplementary Figs. S2b and S3b), and rotational
behavior (Fig. 3d; and Supplementary S2d and S3d) did not
reveal any abnormalities in the HC-Ad-treated rats when
compared with saline-treated age-matched naive controls
(one-way ANOVA followed by Tukey’s multiple comparison
test). The right limb use asymmetry test (Fig. 3c; and see
Supplementary Fig. S3c) also did not reveal any abnormali-
ties except for the groups treated with the highest dose
(1 · 1010 VP of each HC-Ad) when compared with rats trea-
ted with the lowest dose (1 · 108 VP of each HC-Ad) at 1
month (one-way ANOVA followed by Tukey’s multiple
comparison test; p < 0.05) (Supplementary Fig. S2c).
Biodistribution of HC-Ad vector genomes is restricted
to the injected brain hemisphere at all time points
and HC-Ad vector doses tested
The biodistribution of HC-Ad vector genomes was
assessed in the brain, spinal cord, and peripheral organs
5 days, 1 month, 6 months, and 1 year after HC-Ad vector
delivery, using quantitative PCR analysis. At all doses and
time points tested, HC-Ad genomes were restricted to the
injection site in the ipsilateral hemisphere (Fig. 4; and see
Supplementary Fig. S4). HC-Ad vector genomes were below
detectable limits in all peripheral organs, including other
regions of the brain and spinal cord, even at the highest dose
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FIG. 1. Experimental design and neuropathological analysis after treatment with HC-Ads. (A) Diagram of experimental
design used. Adult naive Lewis rats were injected stereotactically in the right striatum with either saline or escalating doses of
high-capacity adenoviral vectors, HC-Ad-TK plus HC-Ad-TetOn-Flt3L (1 · 108, 1 · 109, or 1 · 1010 VP of each vector); after
24 hr, they received ganciclovir (GCV; 25 mg/kg, intraperitoneal), twice daily for up to 10 days. All rats were fed doxycycline
mixed rodent chow (Dox chow) ad libitum for up to 4 weeks starting 2 days before treatment. Groups of rats were evaluated at
5 days (short-term), 30 days (medium-term), 180 days or 365 days (long-term) for biodistribution of vector genomes, neu-
ropathology, peripheral blood cell counts and serum biochemistry, circulating levels of anti-adenovirus neutralizing anti-
bodies, and anti-TK antibodies. In addition, the 30-day, 180-day, and 365-day posttreatment groups underwent
neurobehavioral testing. The rats were killed at experiment end points and organs were harvested for processing. Neuro-
pathological analysis was performed with the brains of rats at 5 days (B) and at 1, 6, and 12 months (C). Neuropathology
results at 1 and 6 months are shown in Supplementary Fig. S1. The brains were processed for Nissl staining to show gross
morphology, and immunocytochemistry with primary antibodies against myelin basic protein (MBP) to label oligoden-
drocytes and myelin sheaths, tyrosine hydroxylase (TH) to label striatal dopaminergic fibers, CD8 to detect CD8 + T cells,
CD68/ED1 for labeling macrophages and activated microglia, MHC-II to label MHC-II + macrophages, microglia, and
immune cells, thymidine kinase (TK) or Fms-like tyrosine kinase-3 ligand (Flt3L) to detect expression of therapeutic trans-
genes in the striatum. Scale bar: 1000 lm for all but TK and Flt3L: 250 lm.
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tested at all time points, thereby highlighting the high safety
profile of this HC-Ad-mediated, combined gene therapy
approach.
Circulating neutralizing anti-adenovirus antibodies
and anti-thymidine kinase antibodies in the serum
of HC-Ad-treated animals
Blood samples were collected from each animal during
euthanasia to measure anti-adenovirus neutralizing anti-
bodies and anti-thymidine kinase antibodies. Serum levels of
anti-Ad neutralizing antibodies were indistinguishable from
background levels at all time points with total HC-Ad doses
of 2 · 108 and 2 · 109 VP. Animals injected with the highest
dose of HC-Ads (2 · 1010 VP) exhibited detectable, albeit low
titers of circulating anti-Ad neutralizing antibodies, consis-
tent with the generation of antibodies against adenoviral
proteins, possibly due to some degree of leakage of the HC-
Ads into the ventricular space (Fig. 5). The highest titers were
exhibited 1 month after vector delivery, *1:64, decreasing to
titers below 1:20 at 6 months and 1 year after HC-Ad de-
livery (Fig. 5). Antibodies against thymidine kinase were also
elevated at 1 year in the serum of animals injected with the
highest dose of HC-Ads (Fig. 6) (one-way ANOVA followed
by Tukey’s multiple comparison test; p < 0.05).
Analysis of blood biochemistry and clinical
laboratory parameters
To detect any possible systemic side effects after delivery
of escalating doses of therapeutic HC-Ads in the brain of
naive Lewis rats, serum biochemistry and blood cell counts
were carried out on blood samples harvested 5 days, 1
month, 6 months, and 1 year posttreatment. Serum bio-
chemical parameters indicated normal liver and renal func-
tions; the serum levels of aspartate aminotransferase (AST),
alanine aminotransferase (ALT), bilirubin, urea, and creati-
nine were found to be within the normal range as seen in
age-matched naive Lewis rats, at all time points and vector
doses tested (Table 1; and see Supplementary Tables S1–S3).
Red and white blood cell counts in the treated animals were
also within normal ranges, indicating that Flt3L expression in
the naive rat brain does not substantially alter the levels of
circulating immune cells.
FIG. 2. High-power magnification images of sections from naive Lewis rats stained with Nissl 5 days, 30 days, 6 months,
and 1 year after intrastriatal administration of escalating doses of HC-Ad-TetOn-Flt3L and HC-Ad-TK. Flt3L, Fms-like
tyrosine kinase ligand-3; TK, thymidine kinase. Scale bar: 200 lm.
276 MUHAMMAD ET AL.
Discussion
There is accumulating evidence that supports the use of
immunotherapies in combination with standard anti-GBM
treatment modalities, that is, surgery, radiotherapy, and
chemotherapy (Sul and Fine, 2010; Vauleon et al., 2010;
Castro et al., 2011; Heimberger and Sampson, 2011; Szabo
and Carpentier, 2011; Weller, 2011). We have developed an
effective immune-gene therapy strategy for treating GBM
that comprises the combined use of conditional cytotoxicity
(HSV1-TK plus systemic delivery of GCV) (Dewey et al.,
1999) and immune stimulation elicited by expressing
human Flt3L (hFlt3L) within the tumor microenvironment
(Ali et al., 2004; Curtin et al., 2006). hFlt3L is effective in
rodents; we have shown its efficacy to treat intracranial
tumors and elicit anti-tumor-specific immune responses in
several intracranial GBM preclinical models in both rats and
mice (Ali et al., 2004, 2005; King et al., 2008a,b; Candolfi
et al., 2009; Curtin et al., 2009; Ghulam Muhammad et al.,
2009; Mineharu et al., 2011). Further, we have also shown
that hFlt3L is capable of recruiting antigen-presenting cells
into the brain microenvironment after adenovirus-mediated
delivery into the striatum of rats (Curtin et al., 2006). Our
treatment strategy involves availability of tumor antigens
and innate immune adjuvants such as high-mobility group
B1 protein (HMGB1) from dead/dying GBM cells initiated
by TK (plus GCV) and uptake of the tumor antigens by
antigen-presenting cells (dendritic cells, DCs), which are
recruited into the tumor microenvironment by Flt3L (Curtin
et al., 2006, 2009). This combined gene therapy approach
also generates immunological memory that protects against
recurrent GBM. It is also effective in models of multifocal,
and peripheral GBMs (King et al., 2008a,b, 2011; Ghulam
Muhammad et al., 2009).
It has been established that there is a high prevalence of
systemic immunity against Ads in the human population
(Chirmule et al., 1999; Nwanegbo et al., 2004; Sumida et al.,
2005), and this could potentially interfere with and com-
promise the efficacy of gene therapies mediated by thera-
peutic Ad-based vectors (Sun et al., 2011). To address this
problem, we developed HC-Ads as delivery platforms for
the therapeutic transgenes TK and Flt3L (Candolfi et al., 2006;
Xiong et al., 2006; King et al., 2008c; Muhammad et al., 2010).
HC-Ads have numerous advantages, including their large
cloning capacity, negligible toxicity, and long-term transgene
expression profile (Parks et al., 1996; Schiedner et al., 1998;
Morral et al., 1999; Thomas et al., 2001a,b; Palmer and Ng,
2005; Schillinger et al., 2005; Toietta et al., 2005; Barcia et al.,
2007). The HC-Ads used in our study were grown with a
helper virus that provides all essential adenoviral functions
for replication in trans. The packaging sequence of the helper
virus is flanked by loxP recombination sites, in 293-Cre cells.
The helper viral genome undergoes recombination that de-
letes the packaging sequence, and thus the helper virus ge-
nome becomes less efficiently packaged than the HC-Ad
genome (Parks et al., 1996; Palmer and Ng, 2003, 2004). With
this production method, titers of contaminating helper virus
are consistently *0.05% of HC-Ad genomes in the final
preparations (Ng et al., 2001; Palmer and Ng, 2003, 2004;
Puntel et al., 2006). Given that in our study the highest dose
injected into the brain was 1 · 1010 VP, the helper virus
contamination would be less than 5 · 106 VP. Furthermore,
we have previously shown negligible levels of inflammation
triggered by the injection of HC-Ad into the naive brain,
even in the presence of a systemic anti-Ad immune response
(Thomas et al., 2000, 2001b; Xiong et al., 2006; Barcia et al.,
2007; King et al., 2008c). This study involves the use of
two HC-Ad vectors: HC-Ad-TK, which expresses TK
FIG. 3. Behavioral assess-





performed before and after
amphetamine treatment in
the animals, at 1 month
(Supplementary Fig. S2), 6
months (Supplementary Fig.
S3), and 1 year (Fig. 2) after
intracranial administration of
escalating doses of HC-Ad-
TK plus HC-Ad-TetOn-Flt3L.
Saline-treated, age-matched
rats were used as controls. (a)
Total locomotor activity; (b)
total rearing activity; (c) right
limb use asymmetry; (d)
asymmetry in rotational
behavior.
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constitutively (Candolfi et al., 2006; King et al., 2008c;
Muhammad et al., 2010), and HC-Ad-TetOn-Flt3L, which
expresses Flt3L under the tight control of a regulatable
mCMV-TetOn expression system (Candolfi et al., 2006; Xiong
et al., 2006; Muhammad et al., 2010). We have considered
putting both treatment cassettes into the same vector, and
the efficacy data using the bicistronic HC-Ad encoding both
therapeutic transgenes have been published previously
(Puntel et al., 2010b). Both approaches have advantages and
disadvantages. The rationale for testing the two-separate-
vector approach is, first, that we can dose each vector/
therapeutic transgene independently. This will be an ad-
vantage in the setting of clinical trials as the toxicity of each
vector can be tested on its own. For the design of the phase 1
trial we will propose a dose-finding safety trial in which the
dose of each vector will be varied individually. Also, because
the phase 1 trial using the combined TK/Flt3L strategy has
been approved by the FDA using two independent first-
generation Ad vectors (14574 IND approved 4/7/11), it was
deemed prudent to keep the clinical trial design as planned
and change only perceived safety issues, that is, the vector
backbone, and the addition of a regulatable transcriptional
switch to turn the expression of Flt3L ‘‘on’’ and ‘‘off’’ ac-
cording to clinical need. Second, there may be an advantage
to expressing the therapeutic transgenes in different cells,
because the dividing cells that are expressing TK will be
killed in the presence of GCV, and thus, if Flt3L is expressed
in that same cell, this would diminish the expression of the
immune stimulatory arm of the therapy. Nevertheless, as a
single high-capacity Ad vector encoding both transgenes has
been produced by us, we will be able to test it in clinical trials
in the future.
We used the CNS-1 GBM rat model to test the safety and
efficacy of the engineered HC-Ads encoding Flt3L and TK
delivered into the tumor mass (Muhammad et al., 2010). This
HC-Ad-mediated anti-GBM gene therapy was also tested in
GBM rat models that were immunized by intradermal in-
jection of an empty Ad vector (i.e., does not express any
transgene). These immunized rats displayed high levels of
circulating neutralizing anti-Ad antibodies, thereby mim-
icking the likely scenario to be encountered during human
clinical trials. We found that the GBM was eradicated in
*70% of rats within 30 days of treatment and that the
therapeutic strategy was effective even in the presence of a
FIG. 4. Biodistribution of HC-Ad-TK plus HC-Ad-TetOn-Flt3L vector genomes after delivery into the striatum. Three
escalating doses of HC-Ad-TK plus HC-Ad-TetOn-Flt3L: (a and d) 1 · 108 VP, (b and e) 1 · 109 VP, and (c and f) 1 · 1010 VP,
were stereotactically injected into the striatum of naive Lewis rats. Ganciclovir (25 mg/kg, intraperitoneal) was injected twice
daily for up to 10 days and doxycycline (Dox) chow was administered ad libitum for up to 4 weeks. Rats were killed at 5-day,
1-month, 6-month, and 1-year end points and tissue samples (25 mg) were harvested from a total of 13 sites/organs: brain
injection site, brain contralateral side, brain stem, cerebellum, lumbar spinal cord, cervical lymph nodes, heart, lung, spleen,
liver, kidney, small gut, and testes. Five microliters of the isolated DNA from each tissue sample was used for qPCR to assess
the biodistribution of the vector genomes. Vector genome quantification results are the average of triplicates for each DNA
sample, and are shown as the ratio of vector genomes per 25 mg of tissue. The dotted line indicates the detection limit. Results
are based on n = 5 per group. The biodistribution data for 5 days (top) and 1 year (bottom) after HC-Ad delivery showed that
the vector genomes were restricted to the brain site of injection (data for 1 and 6 months are shown in Supplementary Fig. S4).
*p < 0.05 versus remaining sites/organs (one-way ANOVA followed by Tukey’s multiple comparison test).
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FIG. 5. Anti-adenovirus neu-
tralizing antibodies in the se-
rum of HC-Ad-treated rats. The
prevalence of anti-adenovirus
neutralizing antibody in the
serum of rats treated with
intracranial injections of esca-
lating doses of HC-Ad-TK
plus HC-Ad-TetOn-Flt3L or
saline is shown. Ganciclovir
(25 mg/kg, intraperitoneal)
was administered twice daily
for up to 10 days and doxy-
cycline (Dox) chow was ad-
ministered ad libitum for up to
4 weeks. The rats were killed 5
days (a), 1 month (b), 6
months (c), and 1 year (d) after
treatment and sera were col-
lected. Low levels of neutral-
izing antibody were detected
at the highest dose (1 · 1010
VP) after 1 month of HC-Ad
delivery. *p < 0.05 versus sa-
line or either of the lower
vector doses (one-way ANO-
VA followed by Tukey’s mul-
tiple comparison test).
FIG. 6. Circulating anti-HSV1-TK antibodies in the serum of HC-Ad-treated rats. Escalating doses of HC-Ad-TK plus
HC-Ad-TetOn-Flt3L, or saline, were stereotactically injected into the striatum of Lewis rats. Ganciclovir (25 mg/kg, intra-
peritoneal) was administered twice daily for up to 10 days and doxycycline (Dox) chow was administered ad libitum for up to
4 weeks. The rats were killed 5 days (a), 1 month (b), 6 months (c), and 1 year (d) after treatment and sera were collected.
Serum from each animal was evaluated for the presence of circulating antibodies specific for thymidine kinase (TK). Cir-
culating anti-TK antibodies were detected at the highest dose (1 · 1010 VP) 1 year after HC-Ad delivery into the naive rat
brain. The titer of anti-TK antibodies is represented as the percent change in signal intensity from sera incubated with cell
lysates from Ad-TK-infected cells when compared with mock-infected cells. Samples were considered positive when the
percent change was ‡ 25%; this threshold is indicated by the dashed line. *p < 0.05 versus saline or either of the lower vector















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































systemic antiadenoviral immune response. Further, long-
term immunological memory protected the cured rats
against tumor rechallenge, even 1 year after treatment
(Muhammad et al., 2010), highlighting the therapeutic effi-
cacy of this approach in countering recurrences of GBM.
Although our combination therapy with HC-Ad-TK and
HC-Ad-TetOn-Flt3L was found to be highly effective and
safe when injected to treat intracranial GBM, the tumor mi-
croenvironment is well known to possess unique structural
features that are significantly different from those of the
surrounding brain tissue (Lorusso and Ruegg, 2008; Pietras
and Ostman, 2010; Charles et al., 2011). Hence, it was critical
to conduct the present study to perform a thorough assess-
ment of the neuropathology, biodistribution and transgene
expression, behavioral impact, as well as any putative sys-
temic and toxicity of HC-Ads when delivered within the
normal adult rat brain parenchyma. Accordingly, escalating
doses of HC-Ads (1 · 108, 1 · 109, or 1 · 1010 VP of each HC-
Ad) were injected into the right striatum and groups of rats
were killed on day 5, 1 month, 6 months, or 1 year post-
treatment and tissue samples were harvested for analysis.
Rats belonging to the 1-month, 6-month, and 1-year post-
treatment groups were also subjected to a panel of neuro-
behavioral tests.
Histopathological analysis of the brain sections did not
reveal any evidence of neurotoxicity or long-term inflam-
mation at the lower doses tested (total HC-Ad dose, 2 · 108 or
2 · 109 VP). At the highest dose tested, that is, a total HC-Ad
dose of 2 · 1010 VP, we observed loss of brain tissue and high
levels of inflammation, suggesting that this dose is unsafe to
the naive rat brain. Infiltrating immune cells were localized
in the vicinity of the injection site in the ipsilateral hemi-
sphere, comprising cells immunopositive for CD8, CD68/
ED1, and MHC-II. Infiltrating immune cells decreased at
6 months and 1 year after HC-Ad vector injection; this may
be attributed in part to the unique regulatable features en-
gineered into the vector that expresses the transgene Flt3L,
that is, its expression is triggered only in the presence of
doxycycline (Dox). The most likely explanation for the in-
flammatory and/or immune mechanisms observed at the
highest dose tested is that the toxicity seen has a similar basis
as that described for first-generation adenoviral vectors
(Thomas et al., 2001a). The highest total dose of HC-Ad tes-
ted (2 · 1010 VP) is cytotoxic to the brain at the earliest time
point, that is, 5 days; the progressive elimination of affected
brain tissue can be detected as a slow shrinkage of the
striatum and enlargement of the ventricles, observed after
1 and 6 months, and is fully established after 12 months. It is
unlikely that a T cell response would have been able to play
any significant role in this cytotoxicity. Given that we used a
gutted adenoviral vector, the turnover of input viral capsids
and the incapacity of infected cells to continue to produce
capsid proteins, would effectively make any infected cells
invisible to anti-viral vector T cells (Barcia et al., 2007). We
have no evidence that immune responses against the trans-
genes were ever generated in our experimental systems. We
decided to test the toxicity of the combined HC-Ads because
in human patients undergoing phase 1 clinical trials for
GBM, the vectors will be delivered in combination. The
toxicities seen at the highest doses are likely elicited by the
high levels of viral protein capsids and not by the therapeutic
transgenes (Gerdes et al., 2000; Thomas et al., 2001a; Hurtado-
Lorenzo et al., 2003; Lowenstein and Castro, 2003, 2004;
Barcia et al., 2006). Also, we evaluated putative toxicities of
the therapeutic HC-Ad vectors only in the presence of gan-
ciclovir or Dox, because in human patients the vectors will be
administered in conjunction with these drugs delivered
systemically. However, in previous studies in rodents it was
shown that ganciclovir does increase the toxicity somewhat
(Cowsill et al., 2000); nevertheless, the main factor in ade-
noviral vector toxicity remains the vector capsid itself, with
ganciclovir playing a minor role, mainly due to the killing of
any dividing cells in the CNS.
It is not known whether infection with HSV will cause an
immune response against the HSV1-TK, which could cross-
react with TK being expressed in the brain from the gutted
adenoviral vector genomes. However, during HSV2 infection
the immune response is directed mainly against envelope
glycoproteins rather than late proteins, such as HSV1-TK.
We have previously shown that in animals preimmunized
with first-generation adenoviral vectors, high-capacity ade-
noviral vector expression lasts for at least 12 months in the
absence of neurotoxicity in the CNS (Barcia et al., 2007). We
have also previously shown that immunization with first-
generation adenoviral vectors of animals injected via the
brain with high-capacity adenoviral vectors 2 months earlier,
fails to cause brain inflammation. We have not looked for
expression of helper virus products because the amount of
helper virus injected is less than 5 · 106; it would be techni-
cally difficult to detect expression of any protein expressed
from the helper virus genome. We have previously also
shown that an Ad dose of 1 · 106 IU delivered into the brain
does elicit low levels of transgene expression and no local
inflammation, and that more than 1 · 107 IU must be injected
into the subcutaneous tissue to cause a systemic immune
response against adenovirus (Barcia et al., 2007).
The biodistribution data revealed that HC-Ad vector ge-
nomes were confined to the brain injection site and did not
leak to other areas of the brain, spinal cord, or peripheral
organs. Interestingly, sustained levels of HC-Ad vector ge-
nomes were seen to persist in the brain injection site for up to
1 year after treatment, suggesting that the cytotoxic effects of
TK or the immune-stimulatory effects of Flt3L could be
‘‘reactivated’’ with the readministration of GCV or Dox, re-
spectively, if required.
Peripheral blood cell counts were found to be within the
normal range and serum biochemical profiles indicated
normal liver and renal functions in rats at all time points and
doses tested. In the groups treated with either escalating HC-
Ad doses or saline, some rats showed higher platelet counts
in comparison with age-matched naive untreated rats.
However, the platelet counts were similar in both the HC-
Ad- and saline-treated controls. Some blood glucose levels
were also seen to be elevated in the treatment groups but
appeared to be similar in both HC-Ad-treated and saline-
treated controls. Analysis of amphetamine-induced total
locomotor activity and total rearing activity also did not reveal
any behavioral abnormalities when compared with saline-
treated age-matched naive controls. We detected low levels
of neutralizing antibodies 1 month after HC-Ad delivery, in
the serum of animals injected with the highest dose of HC-
Ads; antibodies against thymidine kinase were also slightly
elevated 1 year postinjection in the serum of animals injected
with the highest dose of HC-Ads. This could be because,
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although the immune-privileged status of brain can hamper
immune responses against vectors delivered into the brain
parenchyma, leakage into the intraventricular space allows
systemic exposure because the cerebrospinal fluid drains to
the venous circulation, thereby raising the chance of initiat-
ing an antivector immune response. In previous studies, we
have examined preimmunized rats for signs of neurotoxicity.
This was done in the context of achieving long-term ex-
pression (Barcia et al., 2007), or in the context of the treatment
of brain tumors (Muhammad et al., 2010). In the naive brain,
expression from high-capacity Ad vectors stretched to 12
months in the absence of any untoward effects. Equally,
gutted adenoviruses were able to eliminate tumors from
animals preimmunized against adenoviral vectors in the
absence of overt neurotoxicity (King et al., 2008c). Non-
immunized and preimmunized tumor-bearing rats were
treated with HC-Ad-TK and first-generation Ad-TK and the
results show that HC-Ad-TK induced tumor regression and
long-term survival in both nonimmunized and pre-
immunized rats. However, Ad-TK treatment failed in the
preimmunized rats (King et al., 2008c). HC-Ad-TK was effi-
cacious when used in combination with tHC-Ad-TetOn-Flt3L
to treat preimmunized rats with large brain tumors
(Muhammad et al., 2010). HC-Ad-TetOn-Flt3L and HC-Ad-
TK therapy improved survival of tumor-bearing animals
(naive and preimmunized) having a preexisting anti-Ad
immune response (Muhammad et al., 2010).
The analyses performed suggest that the overall safety
profile of the gutted adenoviral vectors, HC-Ads encoding
TK, does match the earlier studies using first-generation Ad-
TK vectors. This is to be expected, as most of the toxicity is
due to the viral capsids, and these are identical for both
vectors. Also, in another study, it has been shown that both
neurotoxicity and systemic toxicity with Ad-TK is similar to
those with HC-Ad-TK (Candolfi et al., 2009). Furthermore,
the gutted adenoviral vectors have an advantage when used
in animals that have been preimmunized against adenovirus.
We have previously shown that treatment of a syngeneic
intracranial glioma model with HC-Ad-TK induced tumor
regression and long-term survival in both nonimmunized
and preimmunized tumor-bearing rats, whereas treatment
with Ad-TK failed in preimmunized tumor-bearing rats
(King et al., 2008c). HC-Ad-TK was efficacious when used
in combination with HC-Ad-TetOn-Flt3L to treat pre-
immunized rats with large brain tumors (Muhammad et al.,
2010). HC-Ad-TetOn-Flt3L and HC-Ad-TK therapy im-
proved survival of tumor-bearing rats exhibiting a preexist-
ing anti-Ad immune response. Ad-TK/Ad-Flt3L, however,
was not efficacious in preimmunized rats (Muhammad et al.,
2010).
The present study, in conjunction with previously pub-
lished work from our laboratory and others, highlights that
GBM and other malignant brain tumors are attractive ‘‘tar-
get’’ diseases for implementing gene therapeutic strategies.
In this respect, delivery of viral vectors in the brain is well
established, both in animal models and also in human pa-
tients enrolled in clinical trials (Immonen et al., 2004; Markert
et al., 2009). Also, the therapeutic efficacy of HC-Ad vectors
expressing transgenes targeted to treat disease conditions
such as brain cancer, colorectal cancer, hyperbilirubinemia,
monogenic hypoalphalipoproteinemia, hemophilia, diabetic
retinopathy, glycogen storage disease, hypertension, and
sensory neuronopathies has been assessed in preclinical
models showing high efficacy (Schillinger et al., 2005; Toietta
et al., 2005; Kiang et al., 2006; McCormack et al., 2006;
Lamartina et al., 2007; Oka et al., 2007; Terashima et al., 2009;
Muhammad et al., 2010; Puntel et al., 2010a; Gonzalez-
Aparicio et al., 2011). Thus, this comprehensive, preclinical
safety and toxicity study will facilitate the implementation of
phase 1 clinical trials for GBM using high-capacity adeno-
viral vectors; it will also lay the foundations for the treatment
of other devastating neurological diseases using HC-Ad-
mediated gene therapy strategies.
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